Integra LifeSciences Stock Forecast, Price & News

Integra LifeSciences (NASDAQ:IART) Frequently Asked Questions

Is Integra LifeSciences a buy right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Integra LifeSciences in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Integra LifeSciences stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IART, but not buy additional shares or sell existing shares.
View analyst ratings for Integra LifeSciences or view top-rated stocks.

How has Integra LifeSciences' stock been impacted by Coronavirus?

Integra LifeSciences' stock was trading at $46.08 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, IART shares have increased by 40.6% and is now trading at $64.81.
View which stocks have been most impacted by COVID-19.

When is Integra LifeSciences' next earnings date?

Integra LifeSciences is scheduled to release its next quarterly earnings announcement on Thursday, February 17th 2022.
View our earnings forecast for Integra LifeSciences.

How were Integra LifeSciences' earnings last quarter?

Integra LifeSciences Holdings Co. (NASDAQ:IART) posted its quarterly earnings data on Monday, November, 1st. The life sciences company reported $0.86 EPS for the quarter, topping the consensus estimate of $0.72 by $0.14. The life sciences company earned $386.86 million during the quarter, compared to analyst estimates of $384.47 million. Integra LifeSciences had a net margin of 14.19% and a trailing twelve-month return on equity of 17.33%. The firm's quarterly revenue was up 4.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.80 earnings per share.
View Integra LifeSciences' earnings history.

When did Integra LifeSciences' stock split? How did Integra LifeSciences' stock split work?

Shares of Integra LifeSciences split on Tuesday, January 3rd 2017. The 2-1 split was announced on Thursday, December 22nd 2016. The newly minted shares were payable to shareholders after the market closes on Wednesday, December 21st 2016. An investor that had 100 shares of Integra LifeSciences stock prior to the split would have 200 shares after the split.

What guidance has Integra LifeSciences issued on next quarter's earnings?

Integra LifeSciences issued an update on its FY 2021 earnings guidance on Tuesday, November, 9th. The company provided earnings per share (EPS) guidance of $3.160-$3.200 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.020. The company issued revenue guidance of $1.54 billion-$1.55 billion, compared to the consensus revenue estimate of $1.54 billion.

What price target have analysts set for IART?

7 equities research analysts have issued 1-year price targets for Integra LifeSciences' stock. Their forecasts range from $65.00 to $88.00. On average, they expect Integra LifeSciences' stock price to reach $76.75 in the next year. This suggests a possible upside of 18.4% from the stock's current price.
View analysts' price targets for Integra LifeSciences or view top-rated stocks among Wall Street analysts.

Who are Integra LifeSciences' key executives?

Integra LifeSciences' management team includes the following people:

• Peter J. Arduini, President, Chief Executive Officer & Director
• Glenn G. Coleman, Chief Operating Officer & Executive Vice President (LinkedIn Profile)
• Carrie Anderson, Chief Financial Officer, Treasurer & Executive VP
• William Compton, Chief Information Officer & Senior Vice President
• Kenneth E. Burhop, Chief Scientific Officer & Vice President

What is Peter J. Arduini's approval rating as Integra LifeSciences' CEO?

173 employees have rated Integra LifeSciences CEO Peter J. Arduini on Glassdoor.com. Peter J. Arduini has an approval rating of 74% among Integra LifeSciences' employees.

Who are some of Integra LifeSciences' key competitors?

Some companies that are related to Integra LifeSciences include Abbott Laboratories (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), Stryker (SYK), Becton, Dickinson and (BDX), Edwards Lifesciences (EW), DexCom (DXCM), Boston Scientific (BSX), IDEXX Laboratories (IDXX), Baxter International (BAX), ResMed (RMD), STERIS (STE), Insulet (PODD), Hologic (HOLX) and Masimo (MASI).
View all of IART's competitors.

What other stocks do shareholders of Integra LifeSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Integra LifeSciences investors own include Boeing (BA), NVIDIA (NVDA), AbbVie (ABBV), Adobe (ADBE), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Intel (INTC), Marvell Technology (MRVL), Alexion Pharmaceuticals (ALXN) and Abbott Laboratories (ABT).

What is Integra LifeSciences' stock symbol?

Integra LifeSciences trades on the NASDAQ under the ticker symbol "IART."

Who are Integra LifeSciences' major shareholders?

Integra LifeSciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Capital Research Global Investors (9.74%), Janus Henderson Group PLC (4.89%), Eaton Vance Management (4.73%), Cooke & Bieler LP (2.81%), Alliancebernstein L.P. (2.48%) and Dimensional Fund Advisors LP (1.56%). Company insiders that own Integra LifeSciences stock include Eric Schwartz, Glenn Coleman, Jeffrey Mosebrook, Lisa Evoli, Michael J Mcbreen, Peter J Arduini, Raymond G Murphy, Richard E Caruso, Stuart Essig and Tru St Partnership, LP.
View institutional ownership trends for Integra LifeSciences.

Which institutional investors are selling Integra LifeSciences stock?

IART stock was sold by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, Janus Henderson Group PLC, Cooke & Bieler LP, Jennison Associates LLC, Eagle Asset Management Inc., Segall Bryant & Hamill LLC, Renaissance Technologies LLC, and Tudor Investment Corp Et Al. Company insiders that have sold Integra LifeSciences company stock in the last year include Eric Schwartz, Glenn Coleman, Jeffrey Mosebrook, Lisa Evoli, Michael J Mcbreen, Raymond G Murphy, Stuart Essig, and Tru St Partnership, LP.
View insider buying and selling activity for Integra LifeSciences or view top insider-selling stocks.

Which institutional investors are buying Integra LifeSciences stock?

IART stock was acquired by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Eaton Vance Management, Fuller & Thaler Asset Management Inc., Pura Vida Investments LLC, Dimensional Fund Advisors LP, Nordea Investment Management AB, Nisa Investment Advisors LLC, and The Manufacturers Life Insurance Company .
View insider buying and selling activity for Integra LifeSciences or or view top insider-buying stocks.

How do I buy shares of Integra LifeSciences?

Shares of IART can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Integra LifeSciences' stock price today?

One share of IART stock can currently be purchased for approximately $64.81.

How much money does Integra LifeSciences make?

Integra LifeSciences has a market capitalization of $5.49 billion and generates $1.37 billion in revenue each year. The life sciences company earns $133.89 million in net income (profit) each year or $2.54 on an earnings per share basis.

How many employees does Integra LifeSciences have?

Integra LifeSciences employs 3,700 workers across the globe.

What is Integra LifeSciences' official website?

The official website for Integra LifeSciences is www.integralife.com.

Where are Integra LifeSciences' headquarters?

Integra LifeSciences is headquartered at 311 ENTERPRISE DRIVE, PLAINSBORO NJ, 08536.

How can I contact Integra LifeSciences?

Integra LifeSciences' mailing address is 311 ENTERPRISE DRIVE, PLAINSBORO NJ, 08536. The life sciences company can be reached via phone at (609) 275-0500, via email at [email protected], or via fax at 609-750-4277.